The weekly litigation news digest is live. Subscribe now

IP Verse

Methods For Reducing Lipoprotein(A) Levels By Administering An Inhibitor Of Proprotein Convertase Subtilisin Kexin-9 (Pcsk9)

Patent No. EP2756004 (titled "Methods For Reducing Lipoprotein(A) Levels By Administering An Inhibitor Of Proprotein Convertase Subtilisin Kexin-9 (Pcsk9)") was filed by Regeneron Pharmaceuticals on Sep 12, 2012. The application was issued on Dec 25, 2019.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
BOEHMERT & BOEHMERT ANWALTSPARTNERSCHAFT MBBSep 25, 2020ENGELHARD
AMGENDec 27, 2019DORRIES
AMGENDec 27, 2019DORRIES, HANS ULRICH , DF-MP DORRIES FRANK-MOLNIA & POHLMAN

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2756004

REGENERON PHARMACEUTICALS
Application Number
EP12761864A
Filing Date
Sep 12, 2012
Status
Opposition Rejected
Apr 19, 2024
Publication Date
Dec 25, 2019
External Links
Slate, EP2756004B1, Google Patents